CAMP

CAMP4 Therapeutics Corp

Sep 16 • 10:02AM ET

2.60

-0.05 -1.71 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-2.57	Insider Own	88.87%	Shs Outstand	20.16M	Perf Week	30.89%
Market Cap	52.52M	Forward P/E	-	EPS next Y	-1.03	Insider Trans	45.34%	Shs Float	20.16M	Perf Month	55.97%
Enterprise Value	20.69M	PEG	-	EPS next Q	-0.47	Inst Own	8.11%	Short Float	1.08%	Perf Quarter	79.63%
Income	-51.78M	P/S	17.45	EPS this Y	84.24%	Inst Trans	-37.34%	Short Ratio	0.28	Perf Half Y	-51.50%
Sales	3.01M	P/B	1.31	EPS next Y	40.69%	ROA	-	Short Interest	0.22M	Perf YTD	-50.10%
Book/sh	1.98	P/C	1.34	EPS next 5Y	50.74%	ROE	-	52W High	12.30 -78.82%	Perf Year	-
Cash/sh	1.94	P/FCF	-	EPS past 3/5Y	-6.52% -	ROIC	-117.85%	52W Low	1.30 99.59%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	44.50%	Volatility	23.78% 14.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.87	EPS Y/Y TTM	-	Oper. Margin	-1785.10%	ATR (14)	0.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.60	Sales Y/Y TTM	-	Profit Margin	-1722.08%	RSI (14)	63.85	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	5.60	EPS Q/Q	-1.10%	SMA20	38.27%	Beta	-	Target Price	11.24
Payout	-	Debt/Eq	0.18	Sales Q/Q	-	SMA50	52.61%	Rel Volume	2.33	Prev Close	2.65
Employees	55	LT Debt/Eq	0.10	Earnings	Aug 14 AMC	SMA200	-21.00%	Avg Volume	787.43K	Price	2.60
IPO	Oct 11, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	7.81% 144.63%	Trades		Volume	235,242	Change	-1.71%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	JP Morgan	Overweight → Neutral
May-27-25	Initiated	Wedbush	Outperform	$8
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	Piper Sandler	Overweight	$18
Nov-05-24	Initiated	JP Morgan	Overweight	$23

Today 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-10-25 07:00AM	CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders (GlobeNewswire) +40.20%
Aug-14-25 04:05PM	CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.16% +7.74%
Jun-30-25 08:00AM	Sequans Appoints Jason W. Cohenour to Board of Directors (Newsfile)
May-16-25 06:00AM	CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) +9.52%
04:05PM	Loading…
May-13-25 04:05PM	CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) -7.92%
Apr-28-25 04:30PM	CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) -10.00% -5.15%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-27-25 04:05PM	CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -10.16%
Mar-18-25 08:00AM	CAMP4 Appoints Multiple Industry Veterans to its Board of Directors (GlobeNewswire)
Mar-04-25 05:24AM	CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 (Insider Monkey) -5.27%
Feb-06-25 08:00AM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.95%
Jan-13-25 08:00AM	CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 04:05PM	CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire) -8.08%
08:00AM	Loading…
Dec-02-24 08:00AM	CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +5.85%
Nov-21-24 04:05PM	CAMP4 Reports Third Quarter 2024 Financial Results (GlobeNewswire) +8.44% -6.40%
Oct-10-24 07:07PM	CAMP4 Announces Pricing of Initial Public Offering (GlobeNewswire)

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
5AM Partners VI, LLC	10% Owner	Sep 11 '25	Buy	1.53	2,941,176	4,499,999	2,941,176	Sep 15 08:12 PM
Polaris Management Co. VII, L.	10% Owner	Sep 11 '25	Buy	1.53	1,307,189	1,999,999	2,825,500	Sep 11 04:59 PM
Nashat Amir	Director	Sep 11 '25	Buy	1.53	1,307,189	1,999,999	2,825,500	Sep 11 04:48 PM
Maricich Yuri	Chief Medical Officer	Sep 11 '25	Buy	1.65	6,060	9,999	6,060	Sep 11 04:25 PM
Gold Kelly	Chief Financial Officer	Sep 11 '25	Buy	1.65	6,060	9,999	67,877	Sep 11 04:24 PM
Mandel-Brehm Josh	Chief Executive Officer	Sep 11 '25	Buy	1.65	6,060	9,999	278,417	Sep 11 04:23 PM
Young Richard A	Director	Sep 11 '25	Buy	1.65	15,151	24,999	170,010	Sep 11 04:22 PM
Northpond Ventures II GP, LLC	10% Owner	Oct 15 '24	Buy	11.00	763,636	8,399,996	763,636	Oct 17 06:34 PM
AH Equity Partners Bio I, L.L.	10% Owner	Oct 15 '24	Buy	11.00	727,272	7,999,992	1,579,885	Oct 17 05:05 PM
Enavate Sciences GP, LLC	10% Owner	Oct 15 '24	Buy	11.00	1,363,636	14,999,996	3,785,802	Oct 17 04:15 PM
Polaris Management Co. VII, L.	10% Owner	Oct 15 '24	Buy	11.00	909,090	9,999,990	909,090	Oct 15 06:00 PM
5AM Partners VI, LLC	10% Owner	Oct 15 '24	Buy	11.00	909,090	9,999,990	2,625,145	Oct 15 05:56 PM
Nashat Amir	Director	Oct 15 '24	Buy	11.00	909,090	9,999,990	909,090	Oct 15 05:49 PM
Schwab Andrew J.	Director	Oct 15 '24	Buy	11.00	909,090	9,999,990	2,625,145	Oct 15 05:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAMP

CAMP4 Therapeutics Corp

Upgrade your FINVIZ experience